MoonLake Immunotherapeutics appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO
Jorge Santos da Silva was previously Senior Partner at McKinsey & Company, Inc.
For almost 15 years, Mr. da Silva was a leader in McKinsey's Pharmaceutical & Medical Products Practice and in the Company's Zurich office.
He led several key groups at McKinsey over the last decade, including the Biotech group and the Biosimilars group, leading the consultancy's thinking in several biotech-related topics.
Over the years, he advised international biopharma and biotechs, on corporate and business-unit strategy, commercial operating models, R&D, organizational design, M&A, joint ventures, and marketing and sales.
Mr. da Silva is a Ph.D. in Neuroscience and has broad scientific experience in molecular-, cellular- and neuro-biology, with several high profiles peer-reviewed publications during his career in Academia.
He performed his research and earned his degrees in different institutions including Cold Spring Harbor Laboratory, the European Molecular Biology Laboratory, and the Universities of Glasgow and Turin.
He is also a Professor and a Board advisor at the School of Medicine at the Minho University in Portugal.
Matthias Bodenstedt was previously a Partner at McKinsey & Company and brings deep experience in the biopharmaceutical industry with a focus on finance and commercial strategy.
At McKinsey, Mr. Bodenstedt served a diverse set of clients, ranging from pre-revenue biotechs to large global pharmaceutical companies.
He was a key advisor on many industry-shaping transactions on the sell- and buy-side, and worked closely with senior executives on topics such as financing, M&A, BD&L, portfolio strategy, and go-to-market strategy and execution. ■